New combo aims to shorten CLL treatment
NCT ID NCT07671378
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 2 trial tests two oral drugs, zanubrutinib and sonrotoclax, in 24 people with untreated high-risk CLL/SLL. The goal is to see if a time-limited treatment guided by minimal residual disease (MRD) can achieve deep remission. Participants take the drugs for up to 27 cycles, with dosing adjusted based on response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- zanubrutinib and sonrotoclax (oral drugs)
- What this could lead to
- If successful, this could offer a time-limited treatment option for high-risk CLL/SLL, potentially reducing the need for lifelong therapy.
- What could go wrong
- This is a small, early-phase trial (24 participants) with no control group. The combination may cause side effects or fail to achieve deep remission, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Jiangsu Province Hospital
RECRUITINGNanjing, Jiangsu, 210000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could bone marrow from deceased donors cure blood cancers?
- New BTK blocker aims to outsmart drug resistance in elderly CLL patients
- New pill shows promise against Hard-to-Treat blood cancers
- New CLL combo aims for Long-Term remission without lifelong pills
- New cocktail aims to tame Slow-Growing blood cancers
- Could a cancer drug tame a blood disorder?